Table 3 Risk for any cardiovascular toxicity by therapy received

Age at first therapy^a

1.01

(0.99–1.03)

1.02

(1.00–1.04)

1.00

(0.95–1.05)

1.00

(0.95–1.05)

1.01

(0.95–1.07)

1.02

(0.96–1.09)

Gender

 Female

105

ref.

ref.

20

ref.

ref.

9

ref.

ref.

 Male

131

1.34

(1.04–1.73)

1.4

(1.08–1.81)

20

1.19

(0.64–2.20)

1.18

(0.63–2.20)

13

1.66

(0.71–3.91)

2.35

(0.93–5.92)

Race

 White

190

ref.

ref.

34

ref.

ref.

17

ref.

ref.

 Non-white

46

1.04

(0.75–1.44)

1.04

(0.75–1.43)

6

0.95

(0.40–2.27)

0.97

(0.41–2.33)

5

2.6

(0.95–7.11)

4.04

(1.35–12.12)

Comorbidities prior to therapy^b

 Hypertension

15

1.09

(0.65–1.84)

1.06

(0.62–1.82)

0

-

-

0

-

-

 Diabetes

6

1.44

(0.64–3.24)

1.42

(0.63–3.21)

0

-

-

0

-

-

 Dyslipidemia

8

0.81

(0.40–1.64)

0.75

(0.37–1.54)

2

1.27

(0.30–5.28)

1.27

(0.30–5.36)

2

2.77

(0.62–12.33)

3.54

(0.77–16.35)